1.
Diabetes Res Clin Pract
; 100(3): e66-9, 2013 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23618553
RESUMO
A potential adverse effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) on the pancreas remains controversial. We evaluated the DPP-4i effects on pancreatic amylase and lipase activity in patients with type 2 diabetes. These enzymes were slightly but significantly increased, suggesting DPP-4i cause a low-grade inflammatory change in the exocrine pancreas.